Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Should You Buy?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) gapped up before the market opened on Monday. The stock had previously closed at $30.66, but opened at $35.42. Nanobiotix shares last traded at $30.2460, with a volume of 14,832 shares.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, October 15th. Guggenheim started coverage on shares of Nanobiotix in a report on Tuesday, September 15th. They set a “buy” rating and a $64.00 target price on the stock. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $46.67.

Get Our Latest Analysis on NBTX

Nanobiotix Stock Down 5.6%

The company has a fifty day moving average price of $30.34 and a 200 day moving average price of $34.20.

Nanobiotix Company Profile

(Get Free Report)

Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy. Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.

Further Reading

Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.